Paper Contents
Abstract
CRISPR-Cas9 has revolutionized gene editing by enabling precise, efficient, and cost-effective genome modifications. This paper highlights the most significant clinical trial findings that demonstrate the therapeutic potential of CRISPR-based treatments for genetic disorders such as Sickle Cell Disease (SCD), Cystic Fibrosis (CF), and Leber Congenital Amaurosis (LCA). Additionally, it explores CRISPRs role in advancing CAR-T cell therapies for hematological malignancies. The paper emphasizes clinical outcomes, treatment efficacy, safety, and future potential for CRISPR in personalized medicine.
Copyright
Copyright © 2025 Dr. Rupak Roy. This is an open access article distributed under the Creative Commons Attribution License.
Paper ID:
IJPREMS50300030768
ISSN:
2321-9653
Publisher:
ijprems